Arrowhead Pharmaceuticals, Inc.ARWRNASDAQ
Loading
Year-over-year book value per share growth
Latest
8.31%
↓ 70% vs avg
Percentile
P74
Within normal range
Streak
2 qtr
Consecutive growthRecovering
Average
28.14%
Historical baseline
| Period | Value |
|---|---|
| Q4 2025 | 8.31% |
| Q3 2025 | -0.77% |
| Q2 2025 | -27.13% |
| Q1 2025 | 1042.29% |
| Q4 2024 | -71.32% |
| Q3 2024 | -42.61% |
| Q2 2024 | -32.08% |
| Q1 2024 | 148.47% |
| Q4 2023 | -39.56% |
| Q3 2023 | -25.04% |
| Q2 2023 | -18.06% |
| Q1 2023 | 16.55% |
| Q4 2022 | -5.51% |
| Q3 2022 | -11.78% |
| Q2 2022 | 4.64% |
| Q1 2022 | 20.23% |
| Q4 2021 | -9.10% |
| Q3 2021 | -7.40% |
| Q2 2021 | -1.98% |
| Q1 2021 | -2.33% |
| Q4 2020 | -1.99% |
| Q3 2020 | -6.71% |
| Q2 2020 | -2.81% |
| Q1 2020 | -3.28% |
| Q4 2019 | 101.01% |
| Q3 2019 | 7.68% |
| Q2 2019 | 11.55% |
| Q1 2019 | 13.18% |
| Q4 2018 | 80.07% |
| Q3 2018 | -10.92% |
| Q2 2018 | -14.65% |
| Q1 2018 | 43.65% |
| Q4 2017 | -11.47% |
| Q3 2017 | -9.70% |
| Q2 2017 | -4.25% |
| Q1 2017 | -8.53% |
| Q4 2016 | 2.80% |
| Q3 2016 | 34.22% |
| Q2 2016 | -20.28% |
| Q1 2016 | -19.87% |